Lipid formulations of amphotericin B.
Amphotericin B has long been the mainstay in the treatment of systemic fungal infections, but its nephrotoxicity limits the dosage that can be used. New lipid-based forms may allow higher dosing with less nephrotoxicity. Unfortunately, these new forms are substantially more expensive, and data from randomized clinical trials of their relative efficacy are as yet limited.
Department of Pharmacy, Methodist Hospitals of Memphis, TN, USA.
E
E
Jones
M
M
Goldman
D000666:Amphotericin B / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics / Q000493:pharmacokinetics; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics / Q000493:pharmacokinetics; D002626:Chemistry, Pharmaceutical; D002986:Clinical Trials as Topic; D003365:Costs and Cost Analysis; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers; D006801:Humans; D007262:Infusions, Intravenous; D007668:Kidney / Q000187:drug effects; D008055:Lipids; D009181:Mycoses / Q000188:drug therapy*; D014018:Tissue Distribution
D000935:Antifungal Agents; D004337:Drug Carriers; D008055:Lipids; D000666:Amphotericin B